Magee Thomson Investment Partners LLC decreased its position in West Pharmaceutical Services Inc. (NYSE:WST) by 18.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 113,500 shares of the medical instruments supplier’s stock after selling 26,500 shares during the period. West Pharmaceutical Services makes up 3.6% of Magee Thomson Investment Partners LLC’s investment portfolio, making the stock its 12th largest position. Magee Thomson Investment Partners LLC owned 0.15% of West Pharmaceutical Services worth $9,263,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Asset Management One Co. Ltd. bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $164,000. Tyers Asset Management LLC bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $178,000. OMERS ADMINISTRATION Corp bought a new stake in shares of West Pharmaceutical Services during the third quarter worth $216,000. US Bancorp DE boosted its stake in shares of West Pharmaceutical Services by 3.9% in the third quarter. US Bancorp DE now owns 2,921 shares of the medical instruments supplier’s stock worth $218,000 after buying an additional 110 shares during the period. Finally, Cigna Investments Inc. New bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $227,000. Hedge funds and other institutional investors own 90.31% of the company’s stock.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Shares of West Pharmaceutical Services Inc. (NYSE:WST) traded up 0.04% on Friday, reaching $81.90. The company had a trading volume of 306,882 shares. The company has a market capitalization of $6.00 billion, a P/E ratio of 42.88 and a beta of 0.94. West Pharmaceutical Services Inc. has a 52 week low of $69.60 and a 52 week high of $88.30. The company has a 50 day moving average of $80.95 and a 200-day moving average of $81.01.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 16th. The medical instruments supplier reported $0.54 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by $0.02. West Pharmaceutical Services had a net margin of 9.27% and a return on equity of 14.54%. The firm earned $382.30 million during the quarter, compared to analysts’ expectations of $387.31 million. During the same period in the previous year, the firm posted $0.47 earnings per share. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. Analysts predict that West Pharmaceutical Services Inc. will post $2.50 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 3rd. Investors of record on Wednesday, April 19th will be given a $0.13 dividend. This represents a $0.52 annualized dividend and a yield of 0.63%. The ex-dividend date is Monday, April 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 28.11%.

TRADEMARK VIOLATION WARNING: “Magee Thomson Investment Partners LLC Has $9.263 Million Stake in West Pharmaceutical Services Inc. (WST)” was first published by Financial Market News and is the property of of Financial Market News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at http://www.financial-market-news.com/magee-thomson-investment-partners-llc-has-9-263-million-stake-in-west-pharmaceutical-services-inc-wst/1406440/.

A number of equities research analysts recently weighed in on the company. Janney Montgomery Scott restated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, December 23rd. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Tuesday, December 27th. Finally, Jefferies Group LLC upped their price objective on West Pharmaceutical Services from $76.00 to $82.00 and gave the stock a “hold” rating in a research note on Tuesday, January 24th.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

5 Day Chart for NYSE:WST

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.